Back to search
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Anaplastic Lymphoma Kinase (ALK)- Positive Tumors trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Anaplastic Lymphoma Kinase (ALK)- Positive Tumors trials you may qualify forMulticenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progress…
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…
BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, incl…
This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexi…
The researchers are doing this study to see if alectinib in combination with duvelisib is a safe and effective time-limited treatment for people with relapsed o…
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung can…
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with plati…
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients